PXD029884 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas - targeted data |
Description | Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma – namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors, and targeted immunotherapies – may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile changes the peptide MHC (pMHC) repertoire. These data reveal a collection of tumor antigens whose presentation levels are selectively augmented following therapy, including several epitopes present at over 1000 copies-per-cell. We leveraged the tunable abundance of MEKi-modulated antigens by targeting 4 epitopes with pMHC-specific T cell engagers and antibody drug conjugates, enhancing cell killing in tumor cells following MEK inhibition. These results highlight drug treatment as a means to enhance immunotherapy efficacy by targeting specific upregulated pMHCs and provide a methodological framework for identifying, quantifying, and therapeutically targeting additional epitopes of interest. |
HostingRepository | PRIDE |
AnnounceDate | 2023-03-11 |
AnnouncementXML | Submission_2023-03-10_21:08:24.435.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | LaurenStopfer |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | No PTMs are included in the dataset |
Instrument | Orbitrap Exploris 480 |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2021-11-23 07:46:03 | ID requested | |
⏵ 1 | 2023-03-10 21:08:25 | announced | |
2 | 2023-11-14 08:37:17 | announced | 2023-11-14: Updated project metadata. |
3 | 2024-10-22 05:43:03 | announced | 2024-10-22: Updated project metadata. |
Publication List
Stopfer LE, Rettko NJ, Leddy O, Mesfin JM, Brown E, Winski S, Bryson B, Wells JA, White FM, MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas. Proc Natl Acad Sci U S A, 119(49):e2208900119(2022) [pubmed] |
Keyword List
submitter keyword: HLA, targeted,MHC, immunopeptidomics, antigen presentation, SureQuant |
Contact List
ForestWhite |
contact affiliation | Department of Biological Engineering, MIT |
contact email | fwhite@mit.edu |
lab head | |
LaurenStopfer |
contact affiliation | MIT |
contact email | lstopfer@mit.edu |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/03/PXD029884 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD029884
- Label: PRIDE project
- Name: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas - targeted data